News coverage about Express Scripts (NASDAQ:ESRX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Express Scripts earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.1640388691405 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Is Express Scripts Holding Company’s (ESRX) ROE Of 23.09% Sustainable? (finance.yahoo.com)
- Diff Fact to Observe: Express Scripts Holding Company (ESRX) ,Nektar Therapeutics (NKTR) (nismagazine.com)
- Lousy Industry Group Rank Keep Express Scripts (ESRX) a Sell – Investorplace.com (investorplace.com)
- Recent Institutional Activity: Visa Inc. (V), Express Scripts Holding Company (ESRX) – Market Movers (financialqz.com)
- Express Scripts Outlook Improves Amid Tax Reform, CVS-Aetna Deal – Benzinga (benzinga.com)
Several research analysts have recently commented on the company. Robert W. Baird restated a “hold” rating and set a $56.00 price target on shares of Express Scripts in a research report on Friday, September 1st. Jefferies Group restated a “buy” rating on shares of Express Scripts in a research report on Thursday, October 26th. Zacks Investment Research upgraded Express Scripts from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research report on Monday, October 16th. Sanford C. Bernstein upgraded Express Scripts from an “underperform” rating to a “market perform” rating in a research report on Wednesday, December 6th. Finally, ValuEngine lowered Express Scripts from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Six analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $70.67.
Express Scripts (NASDAQ:ESRX) traded up $0.17 during trading hours on Tuesday, reaching $68.56. The company had a trading volume of 3,173,145 shares, compared to its average volume of 4,114,208. The stock has a market capitalization of $38,598.32, a price-to-earnings ratio of 9.96, a PEG ratio of 1.01 and a beta of 0.88. Express Scripts has a 52-week low of $55.80 and a 52-week high of $73.52. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.61 and a current ratio of 0.73.
Express Scripts (NASDAQ:ESRX) last released its earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $1.90. The firm had revenue of $24.68 billion during the quarter, compared to analyst estimates of $25.68 billion. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. Express Scripts’s revenue was down 2.9% compared to the same quarter last year. During the same period last year, the business posted $1.74 earnings per share. equities analysts anticipate that Express Scripts will post 7.01 earnings per share for the current fiscal year.
In other Express Scripts news, CEO Timothy C. Wentworth purchased 8,000 shares of the business’s stock in a transaction on Tuesday, October 31st. The shares were bought at an average cost of $61.13 per share, for a total transaction of $489,040.00. Following the completion of the purchase, the chief executive officer now directly owns 98,628 shares in the company, valued at $6,029,129.64. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Phyllis S. Anderson sold 643 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $62.37, for a total value of $40,103.91. The disclosure for this sale can be found here. Company insiders own 0.68% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Express Scripts (ESRX) Stock Price” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://ledgergazette.com/2017/12/12/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-express-scripts-esrx-stock-price.html.
Express Scripts Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.